Skip to content
MarketScale
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

The Centers for Medicare & Medicaid Services (CMS) has established the Office of Health Technology and Products to integrate AI, interoperability, and digital strategies. This new office aims to enhance efficiency across Medicare, Medicaid, and CHIP programs. By centralizing these efforts, CMS seeks to improve healthcare delivery and outcomes.

  • 01The CMS has launched a new office focusing on AI and interoperability.
  • 02The Office of Health Technology and Products will support Medicare, Medicaid, and CHIP programs.
  • 03Centralizing digital strategies aims to improve healthcare delivery and outcomes.

Aug 1, 2026

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

The Centers for Medicare & Medicaid Services (CMS) has established a new Office of Health Technology and Products. This office assumes over 90 responsibilities to lead federal health IT strategy, focusing on areas like AI, interoperability, and claims modernization.

  • 01CMS's new office centralizes health tech authority, focusing on AI and interoperability.
  • 02The office takes on over 90 responsibilities to modernize claims processes.
  • 03CMS aims to lead federal health IT strategy with its new dedicated office.

Aug 1, 2026

Rebuilding Medicine Around Presence: The Future of Physician House Calls with Dr. Yevhen Pavelko, Founder of Inviah Health

Dr. Yevhen Pavelko, founder of Inviah Health, is advocating for the resurgence of physician house calls. He believes that personal interaction can significantly improve patient care and satisfaction. Inviah Health aims to modernize this traditional approach by integrating advanced medical technology.

  • 01Dr. Yevhen Pavelko supports the revival of physician house calls to improve patient care.
  • 02Inviah Health focuses on integrating advanced technology with traditional house call practices.
  • 03Personal interaction between doctors and patients can enhance care and satisfaction.

Jul 31, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512